Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | ALPI | P09923 | 1/20 | 0.35 |
| ▸ | ALPG | P10696 | 1/20 | 0.35 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12017404 | 1.00 | HTR5A (0.36) | HTR5AACHEALPIALPGPLAA | |
| SCHEMBL6937588 | 0.82 | HTR5A (0.35) | HTR5AACHEALPIALPGPLAA | |
| SCHEMBL14329322 | 0.82 | LMNA (0.36) | HTR5AALPIALPGPLAALMNA | |
| SCHEMBL15945437 | 0.81 | ACHE (0.35) | ACHE | |
| SCHEMBL2608930 | 0.80 | ACHE (0.50) | HTR5AACHEALPIALPGPLAA | |
| SCHEMBL17076744 | 0.80 | MEN1 (0.43) | ACHELMNAKMT2A | |
| SCHEMBL659599 | 0.80 | HPGD (0.46) | ACHELMNAHTTSMN1; SMN2OPRK1 | |
| SCHEMBL15651587 | 0.80 | MEN1 (0.43) | ACHELMNAKMT2A | |
| SCHEMBL18712970 | 0.79 | ACHE (0.33) | ACHEGAA | |
| SCHEMBL18712973 | 0.77 | ALDH1A1 (0.33) | ACHEHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170096425-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-04-06 | — | — | US | disclosed |
| WO-2017011776-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2017-01-19 | — | — | WO | disclosed |
| US-20140228349-A1 | 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES | ARRAY BIOPHARMA, INC. | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096425-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | HTR5A 2374/4885ACHE 4540/4885ALPI 2146/4885 |
| US-20140228349-A1 | 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES | JAK1, JAK3, JAK2 | HTR5A 2520/4885ACHE 3869/4885ALPI 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.